OncLive TV

James L. Mohler, MD, discusses the need for genetic counselors in the detection and treatment of prostate cancer.

Larry J. Copeland, MD, discusses the role of chemotherapy in ovarian cancer.

Lawrence D. Kaplan, MD, discusses frontline treatment options in follicular lymphoma.

Sandy Wong, MD, discusses ways to mitigate the toxicities of selinexor in patients with relapsed/refractory multiple myeloma.

Mira Hellmann, MD, discusses the utility of minimally invasive surgery in cervical cancer.

Lori Brisbin, discusses Trapelo, a new automated tool to help increase the number of patients who receive molecular testing as a precision medicine effort.

Kathryn E. Hudson, MD, discusses performing repeat biopsies on patients with relapsed/refractory non–small cell lung cancer.

Howard A. "Skip" Burris, III, MD, FASCO, FACP, chief medical officer and president, Clinical Operations, Sarah Cannon Research Institute, 2019 ASCO president-elect, and a 2014 Giant of Cancer Care® in Drug Development, discusses ongoing research with antibody-drug conjugates (ADCs) in triple-negative breast cancer.

Jacqueline S. Garcia, MD, instructor in Medicine, Department of Medical Oncology, Harvard Medical School, and physician, Dana-Farber Cancer Institute, discusses research with the combination of navitoclax and ruxolitinib (Jakafi) in patients with myelofibrosis.

Afonso Ribeiro, MD, medical director of Advanced Endoscopy and Gastroenterology at Memorial Healthcare System, discusses the criteria that can be used to determine whether a patient with pancreatic cancer is borderline resectable.

Jeff Yorio, MD, discusses the search for biomarkers and using next-generation sequencing in metastatic lung cancer.

Nikhil C. Munshi, MD, discusses the antitumor effect of NKTR-255 in patients with multiple myeloma.

Alan H. Bryce, MD, assistant professor of medicine, Mayo Clinic, discusses the use of next-generation radiopharmaceuticals in prostate cancer.

Sara A. Hurvitz, MD, associate professor at the David Geffen School of Medicine, University of California, Los Angeles (UCLA) medical director of the Jonsson Comprehensive Cancer Center Clinical Research Unit, co-director of the Santa Monica-UCLA Outpatient Oncology Practices, and director, Breast Cancer Clinical Trials Program, UCLA, discusses the evolution of treatment in metastatic HER2-positive breast cancer.

Mark E. Robson, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the application of precision medicine in breast cancer.

Kurt W. Tauer, MD, FACP, discusses the expansion of subtyping in breast cancer.

Michael Wang, MD, discusses the move towards precision medicine in mantle cell lymphoma.

Ruben Mesa, MD, discusses theapproval of a second JAK inhibitor, fedratinib, to join ruxolitinib as a treatment option for patients with myelofibrosis.

Patrick Brown, MD, discusses the encouraging results of blinatumomab (Blincyto) in the AALL1331 trial.

Matthew P. Schlumbrecht, MD, discusses the treatment of women with uterine leiomyosarcoma.

Pablo Ferraro, MD, discusses the use of molecular profiling in pancreatic cancer.

Jean L. Koff, MD, MS, discusses systemic therapies in follicular lymphoma.

Bita Fakhri, MD, MPH, discusses concern over the tumor lysis syndrome that occurred in the CLL14 trial that looked at patients with previously untreated chronic lymphocytic leukemia.

Maria Chaudhry, MBBS, a hematologist at The Ohio State University Comprehensive Cancer Center—James, discusses novel treatment regimens in relapsed/refractory multiple myeloma.

Simon Rule, MD, professor of hematology, University of Plymouth, discusses the next steps for ibrutinib (Imbruvica) and other BTK inhibitors in the treatment landscape of mantle cell lymphoma (MCL).

Ruben A. Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the efficacy of fedratinib (Inrebic) in patients with myelofibrosis who have low platelet counts.

Denise Yardley, MD, discusses the utility of CDK4/6 inhibitors in hormone receptor

Matthew P. Schlumbrecht, MD, discusses remaining challenges in uterine leiomyosarcoma.

Atif Hussein, MD, discusses the evolution treatment in hepatocellular carcinoma.

John Hays, MD, PhD, discusses the progression of immunotherapy in treating patients with ovarian cancer.